Cancer stem cells and their detection using specific cancer stem cell markers- a new strategy for cancer therapies

Khalida I.  Noel; Rana M.  Raoof; Nibras H.  Khamees

doi:10.30574/gscbps.2021.17.3.0357

Authors

Khalida I. Noel Human Anatomy Department, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
Rana M. Raoof Anatomy Department, College of Medicine, University of Mosul, Mousl, Iraq.
Nibras H. Khamees Human Anatomy Department, College of Medicine, Mustansiriyah University, Baghdad, Iraq.

DOI:

https://doi.org/10.30574/gscbps.2021.17.3.0357

Keywords:

SOX2, ALDH1, EZH2, Cancer stem cell, OCT4, NANOG

Abstract

Background: In the previous theories of cancer, they considered that cancer was a homogeneous which mean that the tumor had only tumor cells and for this reason the treatment for any tumor directed to kill these tumor cells. But, with rising of the metastatic cases of cancer patients, another theory have been raised, that the cancer is a heterogeneous disease which composed of tumor cells that previously the chemotherapy and other cancer therapies directed toward them, in addition there is another group of cells, called cancer stem cells (CSCs), these are more aggressive than the tumor cells that can force the poor microenvironment of the cancer tissue and survive and also they are undifferentiated cells so can undergo mitosis to produce more tumor cells and another group of cancer stem cells in contrast to the tumor cells, which considered a post mitotic and not divided.

Objective: Demonstrate some of cancer stem cell markers that considered an important indicators of early cancer development and lately to detect cases of metastasis.

Conclusion: The theory of the presence of cancer stem cells is more acceptable and applicable and so the cancer therapy must be directed to these groups of cancer stem cells.

Metrics

Metrics Loading ...

References

Till JE, Stem cells in differentiation and neoplasia. J Cell Physiol Suppl. 1982; 1: 3-11.

Boiani M, Scholer HR. Regulatory networks in embryo-derived pluripotent stem cells. Nat Rev Mol Cell Biol. 2005; 6: 872-884.

Potten ChS et al. Epithelial stem cells, the mucosal governor. Int j Exp Path. 1997; 78: 219-243.

Santagata S, Ligon KL and Hornick JL, Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am J Surg Pathol. 2007; 31: 836-845.

Kumar S, Singh NP. Review article Stem cells: A new paradigm. Indian J of Human Genetic. 2006; 12: 4-10.

Zeuner A, Todaro M, De Maria R. Colorectal Cancer Stem Cells from the Crypt to the Clinic. Cell Stem Cell. 2014; 15(6): 692-705.

Booth C, Potten CS. Gut instincts: Thoughts on intestinal epithelial stem cells. J Clin Invest. 2000; 105: 1493–1499.

Marshman E, Booth C, Potten CS. The intestinal epithelial stem cell. Bio essays. 2002; 24: 91–98.

Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014; 14(3): 275–291.

Lathia JD. Cancer stem cells: moving past the controversy. CNS Oncology. 2013; 2(6): 465–467.

Kyjacova L, Hubackova S, Krejcikova K, Strauss R, Hanzlikova H, Dzijak R, et al., Radiotherapy-induced plasticity of prostate cancer mobilizes stem-like non-adherent, Erk signaling-dependent cells. Cell death and differentiation. 2015 Jun; 22(6): 898.

Garza –Trevino et al., Understanding the colon cancer stem cells and perspective on treatment. Cancer cell International. 2015; 15: 2.

Deng Q, Tang DG. Androgen receptor and prostate cancer stem cells biological mechanisms and clinical implications. Endocrine-Related Cancer. 2015; 22(6): T209–T220.

Pattabiraman D, Weinberg R, Tackling the cancer stem cells - what challenges do they pose Nature Reviews. Drug Discovery. 2014; 13(7): 497–512.

Borbone E, Troncone G, Ferraro A, Jasencakova Z, Stojic L, Esposito F, et al., Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas. The Journal of Clinical Endocrinology & Metabolism. 1Apr 2011; 96(4): 1029-38.

Li L. EZH2: Novel therapeutic target for human cancer. Biomedicine. 2014; 4: 1.

Yan KS, Lin CY, Liao TW, Peng CM, Lee SC, Liu YJ, et al. EZH2 in cancer progression and potential application in cancer therapy: A friend or foe?. International journal of molecular sciences. 31 May 2017; 18(6): 1172.

Yang YA, Yu J. EZH2, an epigenetic driver of prostate cancer. Protein Cell. 2013; 4: 331–41.

Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al., The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. Oct 2002; 419(6907): 624.

Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010; 18: 185-197.

Kim KH, Roberts CW. Targeting EZH2 in cancer. Nature Medicine. 2016; 22: 128-134.

Ibarra I, Erlich Y, Muthuswamy SK, Sachidanandam R, Hannon GJ, A role for microRNAs in maintenance of mouse mammary epithelial progenitor cells. Genes & development. 15 Dec 2007; 21(24): 3238-43.

Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Molecular cancer research. 1 Mar 2009; 7(3): 330-8.

Moreb JS, Mohuczy D, Ostmark B, Zucali JR, RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4 hydroperoxycyclophosphamide. Cancer Chemother Pharmacol. 2007; 59: 127–36.

Ni C, Zhang Z, Zhu X, Liu Y, Qu D, Wu P, et al. Prognostic value of CD166 expression in cancers of the digestive system: a systematic review and meta-analysis. PloS one. 5 Aug 2013; 8(8): e70958.

Hessman CJ, Bubbers EJ, Billingsley KG, Herzig DO, Wong MH. Loss of expression of the cancer stem cell marker aldehyde dehydrogenase 1 correlates with advanced-stage colorectal cancer. The American Journal of Surgery. 1 May 2012; 203(5): 649-53.

Titulaer MJ, Klooster R, Potman M, Sabater L, Graus F, Hegeman IM, et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol. 2009; 27: 4260-4267.

Endo Y, Deonauth K, Prahalad P, Hoxter B, Zhu Y, Byers SW. Role of Sox-9, ER81 and VE-cadherin in retinoic acid-mediated trans-differentiation of breast cancer cells. PLoS One. 2008 Jul; 16; 3(7): e2714.

Russo MV, Esposito S, Tupone MG, Manzoli L, Airoldi I, Pompa P, et al. SOX2 boosts major tumor progression genes in prostate cancer and is a functional biomarker of lymph node metastasis. Oncotarget. 15 Mar 2016; 7(11): 12372.

Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet. 2000; 24: 372–376.

Atlasi Y, Mowla SJ, Ziaee SA, Bahrami AR. OCT‐4, an embryonic stem cell marker, is highly expressed in bladder cancer. International Journal of Cancer. 1 Apr 2007; 120(7): 1598-602.

Koo BS, Lee SH, Kim JM, Huang S, Kim SH, Rho YS, Bae WJ, Kang HJ, Kim YS, Moon JH, Lim YC. Oct4 is a critical regulator of stemness in head and neck squamous carcinoma cells. Oncogene; Oncogene. 2015; 34: 2317–2324.

Abubaker K, Luwor RB, Zhu H, McNally O, Quinn MA, Burns CJ, Thompson EW, Findlay JK, Ahmed N. Inhibition of the JAK2/STAT3 path-way in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. BMC Cancer. 2014; 14: 317.

Ohnishi K, Semi K, Yamamoto T, Shimizu M, Tanaka A, Mitsunaga K, Okita K, Osafune K, Arioka Y, Maeda T, Soejima H, Moriwaki H, Ya-manaka S, Woltjen K, Yamada Y. Premature termination of reprogramming in vivo leads to cancer development through altered epigene-tic regulation. Cell. 2014; 156: 663-77.

Heurtier V, Owens N, Gonzalez I, et al. The molecular logic of Nanog-induced self-renewal in mouse embryonic stem cells. Nat Commun. 2019; 10: 1109.

Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S and Smith A. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell. 2003; 113: 643-655.

Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, Maeda M, Yamanaka S. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. 2003; 113: 631-642.

Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008; 68: 4311-4320.

Santagata S, Ligon KL, Hornick JL. Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am J Surg Pathol. 2007; 31: 836-845.

Noel KI, Ibraheem MM, Ahmed BS, Hameed AF, Khamees NH, Akkila SS. Expression of Oct4 stem cell marker in benign prostatic hyperplasia and normal tissue around the prostatic carcinoma in a sample of Iraqi patients. Egypt. J. Histol. 2020; 43: 245–254.

Novak D, Hüser L, Elton JJ, Umansky V, Altevogt P, Utikal J. SOX2 in development and cancer biology. Seminars in Cancer Biology. 2020; 67(1): 74-82.